



Overview Proton Therapy

Marco van Vulpen

7th NCS IJlstrum, 27-10-2017




HollandPTC


1



Photon plan - Proton plan



Photon plan (IMRT, 6 bundles)
CTV-PTV margin 2 mm



Proton plan (MFO, 2 bundles)
Robustness 2 mm, 3.5%



HollandPTC

2



Proton therapy in HollandPTC

Proton therapy:

- Strong rationale

Value proposition:

- No value proven up to now
- Highest level of evidence: 4
- Proton centers are expensive

Goal of HollandPTC:

- Proton therapy value proposition

Method:

- Open work space, for RTH community both for care and R&D
- Open knowledge center
- All patients in studies



Life magazine, May 5th, 1958
Proton therapy is the
“fresh hope on cancer”

HollandPTC

3



Contents

- Status of Proton Therapy in the Netherlands
- Core technical uncertainties in proton delivery
- The proton value proposition


HollandPTC

4




Particle Therapy Facilities Worldwide

Particle Therapy Co-operative Group (PTCOG), <http://ptcog.web.psi.ch>, September 2017.



Stand van zaken PTC's

Nederlandse initiatieven



Courtesy J Langendijk

HollandPTC

6



Planningsbesluit Protonen

Ministerie van VWS (WBMV)

- Kernpunten:
 - Vergunningsplicht
 - Maximaal 2.200 patiënten/jaar
 - Maximaal 4 centra (400-600 patiënten/jaar)
 - Looptijd tot 2020
- Onderbouwing:
 - Realistische capaciteit per centrum
 - Optimale geografische spreiding (bereikbaarheid)
 - Optimale regionale samenwerking
 - Betere mogelijkheden voor klinische validatie

Courtesy J Langendijk


HollandPTC

7



Protonentherapie

Indicaties en aantalen



Signalering Protonentherapie (Gezondheidsraad 2009) / Actualisatie NVRO 2016


Courtesy J Langendijk

HollandPTC

8



Δ NTCP Based Patient Selection



HollandPTC

9




NVRO consensus

Drempels voor Δ NTCP

Drempels bij 1 complicatie

Graad	NTCP-drempe
I	Geen indicatie
II	$\geq 10\%$
III	$\geq 5\%$
IV-V	$\geq 2\%$

Aparte rekenregels in geval van meer dan 1 complicaties worden meegenomen




HollandPTC

10



Step 3: NTCP-profiles

Protonen versus fotonen




HollandPTC
Courtesy J Langendijk



11

Verwijslogistiek

Workflow



HollandPTC

12



Landelijke spelers

Implementatie

- DUPROTON
 - Samenwerkingsverband tussen 4 initiatieven / 7 betrokken centra
 - Taken:
 - Richtlijnen
 - Uniforme behandelprotocollen en workflows
 - Landelijke database voor prospectieve dataregistratie
 - Gezamenlijk wetenschappelijk onderzoek
- LPPT: Landelijk Platform Protonen Therapie
 - Vertegenwoordiging vanuit alle radiotherapie afdelingen in Nederland
 - Taken:
 - Indicatieprotocollen
 - Verwijslogistiek

HollandPTC

13



Implementatie

- Expert Groep Protonen ZiN
 - Leden: ZiN, DUPROTON, NVRO, ZN, NZA, ZonMw, VWS, LPPT, NFK
 - Toezicht op klinische implementatie van protonentherapie

Landelijke database

- ProTRAIT (Proton Therapy IT ReseArch InfrasTructure)
 - WP2 registratie bepaald door:
 - Nationale Indicatie Protocollen (LPPT)
 - Uniforme richtlijnen uitvoering (DUPROTON)
 - Commissie Toxiciteit (NVRO)
 - Kanker Registratie (IKNL) (Sustainability)
 - Rol IKNL:
 - Datamanagement registraties
 - Epidemiologie / statistiek (THINC)
 - Quality assurance

Courtesy J Langendijk



HollandPTC

14




Clinical implementation


Rapid learning health care system




Anatomy Changes




Dosimetric Changes




Core uncertainties



Robust Against Errors




Scanning Beam Potential



21




Technology Advances




Future Potential of Proton Therapy


Proton Therapy Development Lag = ~17 Yrs.



Value of Proton therapy in Care Chain? Example oesophagus



Oesophagus Cancer




medical
data &

Erasmus MC
Universitair Medisch Centrum Rotterdam

LUMC
LEIDSE UNIVERSITAIR MEDISCH CENTRUM

Courtesy SJ Frank
TU Delft

Value Proposition- Esophagus




Lin SH et al. 2015

Courtesy SJ Frank

PT for Nasopharynx/Oropharynx Ca

50%+ reduction in feeding tubes

Proton Therapy (IMPT)




Frank SJ et al. IJROBP 2014

NCI Supported Randomized Trials

1. Oropharyngeal Cancer
2. Esophageal Cancer
3. Stage II-IIIB Non-Small-Cell Lung Cancer
4. Stage I, selected stage II & recurrent NSCLC
5. Glioblastoma
6. Prostate Cancer

Technology Development Lifecycle



Roadblocks for Proton Therapy

1. A limited number (14) of proton therapy centers to publish data and average time to publication
2. Varying Definitions of Medical Necessity
3. Lack of Validity and Accuracy in Insurance Companies Medical Policies
4. Only a few randomized studies
5. Required resources and cost of treatment


Courtesy SJ Frank

HollandPTC


30



Barriers for Rapid Proton Therapy Adoption



Rapid Adoption of Proton Therapy is Close



Thank you for your attention

- Status of Proton Therapy in the Netherlands
- Technical uncertainties in proton delivery
- The proton value proposition

